Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Esperion Therapeutics, Inc. - Common Stock (NQ:ESPR)

3.850 -0.230 (-5.64%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Esperion Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Esperion to Participate in Jefferies London Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Report Third Quarter 2023 Financial Results on November 7
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
5 Analysts Have This to Say About Esperion Therapeutics ↗
 
Via Benzinga
News headline image
Analyst Expectations for Esperion Therapeutics's Future ↗
 
Via Benzinga
News headline image
Analyst Ratings for Esperion Therapeutics ↗
 
Via Benzinga
News headline image
"CLEAR" Progress At Esperion ↗
Esperion Therapeutics, Inc. continues to showcase their positive CLEAR data, with two oral presentations at the European Society of Cardiology 2023 Congress. Here is a closer look at some highlights. 
Via Talk Markets
News headline image
American College of Cardiology Program to Increase Cholesterol Screenings
From Esperion Therapeutics, Inc.; The American College of Cardiology
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Why Is Esperion Therapeutics Stock Trading Higher Today? ↗
Esperion Therapeutics Inc (NASDAQ: ESPR) announced the presentation of results from two CLEAR Outcomes Study Late-Breakers at the European  
Via Benzinga
News headline image
Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Reports Second Quarter 2023 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in BTIG Virtual Biotechnology Conference 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Report Second Quarter 2023 Financial Results on August 1
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023
Cardiovascular risk reduction with bempedoic acid shown via the Cholesterol Treatment Trialists’ (CTT) Major Vascular Event endpoint is comparable to the normalized risk reduction with statins observed... 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Verastem To Rally Around 287%? Here Are 10 Other Analyst Forecasts For Thursday ↗
Piper Sandler boosted the price target for Accenture plc (NYSE: ACN) from $250 to $316. Piper Sandler analyst Arvind Ramnani upgraded the stock from Underweight to Neutral. Accenture shares rose 1.1%... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
It's time to start breaking down the biggest pre-market stock movers for Thursday as we get ready for another busy day of trading! 
Via InvestorPlace
News headline image
Esperion to Present New Key Science at the American Diabetes Association’s 83rd Scientific Sessions 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Present Additional Analyses from the Landmark CLEAR Outcomes Study at ENDO 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders
From Esperion Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.